Special Issue

Metabolic Biomarkers and Gut Microbiota in Adults with Prediabetes

Message from the Guest Editors

The development of prediabetes is associated with changes in the gut microbiota, which in turn, affect metabolism and increase the risk of developing type 2 diabetes. This Special Issue explores the latest research in identifying metabolic biomarkers and their association with gut microbiota in adults with prediabetes. It aims to provide a comprehensive understanding of the complex relationship between metabolic health, gut microbiota, and prediabetes. The scope of this Special Issue includes the identification and validation of biomarkers associated with prediabetes and the gut microbiota, the elucidation of underlying mechanisms, and the development of interventions that target the gut microbiota to improve metabolic health. Overall, this Special Issue will contribute to a better understanding of the role of gut microbiota and metabolic biomarkers in prediabetes. The articles will provide valuable insights for clinicians, researchers, and policymakers in developing effective strategies for the prevention and treatment of prediabetes and type 2 diabetes.

Guest Editors

Dr. Xuhuiqun Zhang

Complete Genomics Inc., San Jose, CA 95134, USA

Dr. Yen Chin Koay

School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2006, Australia

Deadline for manuscript submissions

closed (15 January 2024)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/175046

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

